


GSK delivers strong 2022 performance

“2022 was a landmark year for GSK delivering the step change in performance we committed to, driven by strong growth in specialty medicines and vaccines, including record sales for our shingles vaccine. We enter 2023 with good momentum, underpinning confidence in our ambitious sales and profit outlooks for 2026. At the same time, we continue to build a stronger portfolio and pipeline based on infectious diseases and the science of the immune system. This momentum, together with further targeted business development, means GSK will also be in a strong position to deliver growth from 2026 onwards.”

Emma Walmsley
CEO, GSK



Specialty Medicines

£11.3bn +29%
+15% excluding COVID-19 solutions

Vaccines

£7.9bn +11%
+17% excluding COVID-19 solutions

General Medicines

£10.1bn +1%

Total EPS

110.8p +18%

Adjusted EPS

139.7p +15%

Adjusted operating profit

£8.2bn +14%

Free cash flow

£3.3bn

Dividend

61.25p

Pipeline

69

Vaccines and medicines

Journalists/media see press release on www.gsk.com for full details on FY 2022.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 67 to 69 of the press release.

References to growth are at constant exchange rates (CER) unless stated otherwise.

The amounts presented above for continuing operations and Adjusted results exclude the Consumer Healthcare business discontinued operation.